Last update 30 Mar 2025

Ranibizumab biosimilar (Xbrane Biopharma)

Overview

Basic Info

Drug Type
Fab fragment, Biosimilar
Synonyms
Ranibizumab Biosimilar (Xbrane Biopharma AB), Xlucane, 雷珠单抗生物类似药(Xbrane Biopharma AB)
+ [1]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Choroidal Neovascularization
European Union
09 Nov 2022
Choroidal Neovascularization
Iceland
09 Nov 2022
Choroidal Neovascularization
Liechtenstein
09 Nov 2022
Choroidal Neovascularization
Norway
09 Nov 2022
Diabetic macular oedema
European Union
09 Nov 2022
Diabetic macular oedema
Iceland
09 Nov 2022
Diabetic macular oedema
Liechtenstein
09 Nov 2022
Diabetic macular oedema
Norway
09 Nov 2022
Diabetic Retinopathy
European Union
09 Nov 2022
Diabetic Retinopathy
Iceland
09 Nov 2022
Diabetic Retinopathy
Liechtenstein
09 Nov 2022
Diabetic Retinopathy
Norway
09 Nov 2022
Retinal vein occlusion-related macular edema
European Union
09 Nov 2022
Retinal vein occlusion-related macular edema
Iceland
09 Nov 2022
Retinal vein occlusion-related macular edema
Liechtenstein
09 Nov 2022
Retinal vein occlusion-related macular edema
Norway
09 Nov 2022
Wet age-related macular degeneration
European Union
09 Nov 2022
Wet age-related macular degeneration
Iceland
09 Nov 2022
Wet age-related macular degeneration
Liechtenstein
09 Nov 2022
Wet age-related macular degeneration
Norway
09 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
582
(Xlucane (Proposed Ranibizumab Biosimilar))
jilokuinzw(uafmgezvdl) = uhqsrgemyi ngyryvltmb (zjnspleyvq, izxxwcsezv - hwackjogjx)
-
13 Nov 2023
Lucentis (Ranibizumab)
(Lucentis (Ranibizumab))
jilokuinzw(uafmgezvdl) = wogrzkobyr ngyryvltmb (zjnspleyvq, jpehrgcmuu - whuvaiwdph)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free